Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
Authors
Keywords
-
Journal
GASTROENTEROLOGY
Volume 162, Issue 2, Pages 454-467
Publisher
Elsevier BV
Online
2021-10-29
DOI
10.1053/j.gastro.2021.10.029
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
- (2021) Corey A Siegel et al. GUT
- SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
- (2021) James L Alexander et al. Lancet Gastroenterology & Hepatology
- Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination
- (2021) Eun‐Ju Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”
- (2021) Rossella Talotta CLINICAL IMMUNOLOGY
- Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
- (2021) Michael Mor et al. PLoS Pathogens
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon
- (2021) Karolina Akinosoglou et al. CLINICAL IMMUNOLOGY
- Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies
- (2021) Serre-Yu Wong et al. GASTROENTEROLOGY
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
- (2021) Nicholas A Kennedy et al. GUT
- Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
- (2021) Nicholas A Kennedy et al. GUT
- Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
- (2021) Stefania Dispinseri et al. Nature Communications
- High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
- (2021) Jake A Ruddy et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications
- (2021) Nabeel Khan et al. GASTROENTEROLOGY
- Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study
- (2021) Gilaad G Kaplan et al. GUT
- Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease
- (2021) Joelynn Dailey et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
- (2021) David Hagin et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients
- (2021) Neil Chanchlani et al. Journal of Crohns & Colitis
- Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
- (2021) Mayme Marshall et al. PEDIATRICS
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
- (2021) Amir Massarweh et al. JAMA Oncology
- Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease
- (2021) Michael D. Kappelman et al. GASTROENTEROLOGY
- Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
- (2020) Erica J. Brenner et al. GASTROENTEROLOGY
- Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
- (2020) Wenhua Liang et al. JAMA Internal Medicine
- Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases
- (2020) Aristo Vojdani et al. CLINICAL IMMUNOLOGY
- Determinants of COVID-19 disease severity in patients with cancer
- (2020) Elizabeth V. Robilotti et al. NATURE MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities
- (2020) Shatha K. Alyammahi et al. INFECTION GENETICS AND EVOLUTION
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
- (2018) Shimpei Shirai et al. INFLAMMATORY BOWEL DISEASES
- Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy
- (2018) Perry K Pratt et al. INFLAMMATORY BOWEL DISEASES
- Evidence-based clinical practice guidelines for inflammatory bowel disease
- (2018) Katsuyoshi Matsuoka et al. JOURNAL OF GASTROENTEROLOGY
- Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy
- (2016) Jennifer deBruyn et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study
- (2015) Odile Launay et al. Journal of Crohns & Colitis
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2014) J.F. Rahier et al. Journal of Crohns & Colitis
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
- (2013) Chang Kyun Lee et al. Journal of Crohns & Colitis
- Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA Toxicity Grading Scale Guidance
- (2012) Josephine M. Norquist et al. Human Vaccines & Immunotherapeutics
- Normal Response to Vaccines in Inflammatory Bowel Disease Patients Treated with Thiopurines
- (2011) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease
- (2009) Gil Y Melmed et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started